We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we'll assume that you are OK with this.     OK  No, I would like to know more...
Home / About Novasep / Media & Events / Press releases / Novasep expands its HPAPI manufacturing capacity in Le Mans for innovative cancer therapies

Novasep expands its HPAPI manufacturing capacity in Le Mans for innovative cancer therapies

Novasep expands its HPAPI manufacturing capacity in Le Mans for innovative cancer therapies
12 May 2021

• Novasep continues to consolidate its position as a leading CDMO for the production of innovative and targeted molecules to treat cancer by investing in additional capacity
• Responds to increasing customer demand for manufacturing services for Antibody Drug Conjugates (ADCs)
• More than 30 full-time jobs to be created

 

Lyon, France – May 12, 2021 - Novasep, a leading supplier of services and technologies for the life sciences industry, is pleased to announce today a further expansion of its Highly Potent Active Pharmaceutical Ingredients (HPAPIs) manufacturing capabilities on its Le Mans (72 – France) site. This new step underlines customers' confidence in Novasep’s expertise in HPAPIs & ADCs and reinforces Novasep’s position as a leading CDMO for the production of innovative and targeted molecules to treat cancer.

This site, which has already benefitted from significant investment, continues to exhibit strong growth as a result of longstanding collaborations with major pharmaceutical companies & new partnerships with biotechnology innovators. To support this growth and sustain the increase in both clinical & commercial production capacity, Novasep is recruiting more than 30 people on this site, combined with an investment of more than €4 million.

Novasep has been a key partner to innovators in the ADC arena for more than 15 years. With a strong pipeline of customer’s clinical drug candidates leading to a number of recent ADC drug approvals, Novasep’s strategy of offering integrated development and manufacturing services for both payloads & bioconjugation is now bearing fruit. The state-of-the-art bioconjugation facility, launched in 2017 with an investment of €12 million, delivers cGMP ADC batches to customers and was successfully inspected by the ANSM (French regulatory drug authorities) in 2021. This demonstrates once again Novasep's ability to offer flexible and reliable manufacturing solutions to oncology drug innovators, leveraging specialist technologies and expertise.

Dr. Michel Spagnol, Chairman and CEO of Novasep said "We are pleased to continue our development in strategic markets such as HPAPIs and ADCs, and to participate in the fight against cancer for the benefit of patients. Specifically, this expansion allows us to create more than 30 full-time jobs in Le Mans”.

About Novasep
Novasep offers flexible contract development & manufacturing (CDMO) solutions for small molecule APIs & biopharmaceuticals to innovators. We propose a wide range of flexible cGMP manufacturing assets on multiple sites with an outstanding regulatory track record. We are a world leader in a number of specialized technologies including HPAPIs, ADCs, hazardous & cryogenic chemistry & industrial chromatography (batch and continuous).

Press contact
Thomas Goldberg
Communication Project Manager
press@novasep.com

Novasep Icon PDF 2021 05_PR LMS Expansion_EN

Novasep Icon PDF 2021 05_PR LMS Expansion_FR

Novasep Icon PDF 2021 05_PR LMS Expansion_DE


Back to full list of events

You can stay on this page and select more documents or you can directly download the brochure(s) you selected

Your brochure is ready!

X

You can stay on this page and select more documents or you can directly download the brochure(s) you selected

Give us your feedback!